Business Description
CG Oncology Inc
NAICS : 541714
SIC : 2833
ISIN : US1569441009
Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 407.1 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.06 | |||||
| 9-Day RSI | 52.97 | |||||
| 14-Day RSI | 51.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.62 | |||||
| Quick Ratio | 13.62 | |||||
| Cash Ratio | 13.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1893200 | |||||
| Net Margin % | -1611600 | |||||
| FCF Margin % | -682800 | |||||
| ROE % | -23.94 | |||||
| ROA % | -8.65 | |||||
| ROIC % | -201.87 | |||||
| ROC (Joel Greenblatt) % | -3671.36 | |||||
| ROCE % | -10.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 909.33 | |||||
| EV-to-EBIT | -151.25 | |||||
| EV-to-Forward-EBIT | -38.75 | |||||
| EV-to-EBITDA | -151.28 | |||||
| EV-to-Revenue | 2863425 | |||||
| EV-to-FCF | -414.1 | |||||
| Price-to-Net-Cash | 15.75 | |||||
| Earnings Yield (Greenblatt) % | -0.66 | |||||
| FCF Yield % | -0.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGON
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CG Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.001 | ||
| EPS (TTM) ($) | -0.347 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 51.82 | ||
| 14-Day ATR ($) | 2.841143 | ||
| 20-Day SMA ($) | 38.132 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 28.55 - 50.23 | ||
| Shares Outstanding (Mil) | 66.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CG Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CG Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CG Oncology Inc Frequently Asked Questions
What is CG Oncology Inc(CGON)'s stock price today?
The current price of CGON is $43.00. The 52 week high of CGON is $50.23 and 52 week low is $28.55.
When is next earnings date of CG Oncology Inc(CGON)?
The next earnings date of CG Oncology Inc(CGON) is .
Does CG Oncology Inc(CGON) pay dividends? If so, how much?
CG Oncology Inc(CGON) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers